Biotech
CSL Limited
2
Articles
Mentioned
Top Role
Mar 24, 2026
First Mention
Apr 11, 2026
Last Mention
0.95
Relevance Score
Coverage Timeline
April 2026
Apr 11, 2026
Sanofi and CSL (Seqirus) already own the differentiated, adjuvanted, and cell-based segments.
March 2026
CRISPR Therapeutics’ CS37 in Hemophilia B: Breakthrough Candidate or Regulatory Gamble?
Pipeline
Competitor
Mar 24, 2026
CS37 is in direct competition with current gene therapies like CSL Behring’s Hemgenix.